Bharat Biotech’s Covaxin has received the nod from the Subject Expert Committee (SEC) on Covid-19 for the emergency use approval of the vaccine on 2-18 age groups.
Bharat Biotech has apparently achieved positive results for the phase 2 and phase 3 trials on individuals aged between 2-18.
“After detailed deliberation, the committee recommended for grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in an emergency situation,” the statement from SEC read.
While the advised gap between the first and second dose of Covaxin in India is 28 days, it varies for the 2-18 age group.
Two doses of the vaccine need to be administered 20 days apart.
“This represents one of the first approvals worldwide for Covid-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thank the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children,” Bharat Biotech stated.
Andhra Pradesh and Telangana are finally done with their poll campaigns and there is a…
Director Shankar has been working with shambolic timelines of late. He has been taking forever…
Andhra Pradesh chief minister YS Jagan Mohan Reddy rarely goes on family holidays and he…
Directed by Vamsi Jonnalagadda, "Nee Dhaarey Nee Katha" is a music-based film that promises an…
Last week, Nagababu shared a tweet in which he mentioned that those are by JSP's…
Siddharth, a distinguished Pan-Indian actor known for his unconventional script choices, celebrates 21 years in…